REGN Quantitative Stock Analysis

Of 22 guru strategies Validea tracks, Regeneron (REGN) rates highest under its Benjamin Graham Value Investor model with a 71% score — below Validea's 80% threshold for strategy interest — reflecting solid fundamentals but mixed valuation. The deep-value screen (seeking low P/B and P/E, low debt, and steady long-term earnings) flags REGN as a large-cap growth biotech that passes sales, current ratio, long-term debt relative to net current assets and long-term EPS growth tests, but fails the P/E and price/book tests. The report underscores the methodology's focus and places the firm in the Biotechnology & Drugs sector, noting the rating reflects the author's analysis.

Analysis

Validea's guru fundamental report ranks Regeneron Pharmaceuticals (REGN) highest under its Benjamin Graham Value Investor model out of 22 strategies with a 71% score, which sits below Validea's 80% threshold for strategy interest and well under 90% for strong interest. The report classifies REGN as a large-cap growth company in the Biotechnology & Drugs sector, framing the assessment squarely as a valuation-versus-fundamentals judgement.

REGN passes Validea's tests for sales, current ratio, long-term debt relative to net current assets, and long-term EPS growth, indicating operational resilience and a conservative balance sheet under the model's criteria. It fails the P/E and price/book tests, meaning market multiples remain elevated relative to Benjamin Graham-style deep-value thresholds, creating a disconnect between healthy fundamentals and headline valuation metrics.

The sentiment signal attached to the note is mildly positive (sentiment score 0.25) and the estimated market impact is low (0.2), so the publication itself is unlikely to be a major catalyst. Investors should therefore view this as a valuation check: maintain attention on upcoming earnings and any movement in P/E and P/B that would move the stock toward the model's 80%+ interest threshold before materially changing positioning.

Key Decisions for Investors

• Do not initiate a full position solely on this Validea report; consider waiting for valuation improvement (P/E and P/B compressing toward Graham thresholds) or a clear pullback before adding material exposure
• Existing holders may continue to hold given passes on sales, current ratio, debt and long-term EPS growth, but trim exposure or implement hedges if multiples expand further or growth indicators deteriorate
• Use a re-rating to a Validea score above 80% or confirmed earnings/outlook beats as a pragmatic buy trigger rather than the report alone, and size positions consistent with biotech allocation limits given low market-impact signals
• Monitor quarterly EPS trends and the P/E and price/book trajectories closely; if those metrics begin to align with Graham criteria, reassess conviction and consider incremental purchases